282 related articles for article (PubMed ID: 34025586)
1. Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective.
Nista F; Corica G; Castelletti L; Khorrami K; Campana C; Cocchiara F; Zoppoli G; Prior A; Rossi DC; Zona G; Ferone D; Gatto F
Front Endocrinol (Lausanne); 2021; 12():677919. PubMed ID: 34025586
[TBL] [Abstract][Full Text] [Related]
2. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
Coopmans EC; Korevaar TIM; van Meyel SWF; Daly AF; Chanson P; Brue T; Delemer B; Hána V; Colao A; Carvalho D; Jaffrain-Rea ML; Stalla GK; Fajardo-Montañana C; Beckers A; van der Lely AJ; Petrossians P; Neggers SJCMM
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32589751
[TBL] [Abstract][Full Text] [Related]
3. Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands.
Wildemberg LE; da Silva Camacho AH; Miranda RL; Elias PCL; de Castro Musolino NR; Nazato D; Jallad R; Huayllas MKP; Mota JIS; Almeida T; Portes E; Ribeiro-Oliveira A; Vilar L; Boguszewski CL; Winter Tavares AB; Nunes-Nogueira VS; Mazzuco TL; Rech CGSL; Marques NV; Chimelli L; Czepielewski M; Bronstein MD; Abucham J; de Castro M; Kasuki L; Gadelha M
J Clin Endocrinol Metab; 2021 Jun; 106(7):2047-2056. PubMed ID: 33686418
[TBL] [Abstract][Full Text] [Related]
4. Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly.
Losa M; Garbin E; Pedone E; Mortini P
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32609842
[TBL] [Abstract][Full Text] [Related]
5. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly.
Coopmans EC; Schneiders JJ; El-Sayed N; Erler NS; Hofland LJ; van der Lely AJ; Petrossians P; Potorac J; Muhammad A; Neggers SJCMM
Eur J Endocrinol; 2020 Jun; 182(6):595-605. PubMed ID: 32375119
[TBL] [Abstract][Full Text] [Related]
6. Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment.
Prencipe N; Bona C; Cuboni D; Parasiliti-Caprino M; Berton AM; Fenoglio LM; Gasco V; Ghigo E; Grottoli S
Pituitary; 2021 Apr; 24(2):242-251. PubMed ID: 33164134
[TBL] [Abstract][Full Text] [Related]
7. The Multibiomarker Acro-TIME Score Predicts fg-SRLs Response: Preliminary Results of a Retrospective Acromegaly Cohort.
Chiloiro S; Moroni R; Giampietro A; Angelini F; Gessi M; Lauretti L; Mattogno PP; Calandrelli R; Tartaglione T; Carlino A; Gaudino S; Olivi A; Rindi G; De Marinis L; Pontecorvi A; Doglietto F; Bianchi A
J Clin Endocrinol Metab; 2024 Apr; 109(5):1341-1350. PubMed ID: 37975821
[TBL] [Abstract][Full Text] [Related]
8. GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil.
Manosso KZB; Sampaio CL; Kasuki L; Antunes X; Gadelha MR; Boguszewski CL
Endocrine; 2021 Oct; 74(1):146-154. PubMed ID: 34041695
[TBL] [Abstract][Full Text] [Related]
9. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.
Chiloiro S; Mazziotti G; Giampietro A; Bianchi A; Frara S; Mormando M; Pontecorvi A; Giustina A; De Marinis L
Pituitary; 2018 Jun; 21(3):302-308. PubMed ID: 29397538
[TBL] [Abstract][Full Text] [Related]
10. Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.
Samson SL; Nachtigall LB; Fleseriu M; Gordon MB; Bolanowski M; Labadzhyan A; Ur E; Molitch M; Ludlam WH; Patou G; Haviv A; Biermasz N; Giustina A; Trainer PJ; Strasburger CJ; Kennedy L; Melmed S
J Clin Endocrinol Metab; 2020 Oct; 105(10):e3785-97. PubMed ID: 32882036
[TBL] [Abstract][Full Text] [Related]
11. Effects of acromegaly treatment on left ventricular systolic function assessed by speckle tracking echocardiography in relation to sex differences: results from a prospective single center study.
Popielarz-Grygalewicz A; Stelmachowska-Banaś M; Raczkiewicz D; Czajka-Oraniec I; Zieliński G; Kochman W; Dąbrowski M; Zgliczyński W
Front Endocrinol (Lausanne); 2023; 14():1154615. PubMed ID: 37223021
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.
Brzana J; Yedinak CG; Gultekin SH; Delashaw JB; Fleseriu M
Pituitary; 2013 Dec; 16(4):490-8. PubMed ID: 23184260
[TBL] [Abstract][Full Text] [Related]
13. Real-life data of Pasireotide LAR in acromegaly: a long-term follow-up.
Urbani C; Dassie F; Zampetti B; Mioni R; Maffei P; Cozzi R; Bogazzi F
J Endocrinol Invest; 2024 Jul; 47(7):1733-1741. PubMed ID: 38244140
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly.
Ruiz S; Gil J; Biagetti B; Venegas E; Cámara R; Garcia-Centeno R; Gálvez MÁ; Picó A; Maraver S; González I; Abellán P; Trincado P; Herrera M; Olvera P; Xifra G; Bernabeu I; Serra-Soler G; Azriel S; García L; Carvalho D; Jordà M; Valassi E; Puig J; Puig-Domingo M
Clin Endocrinol (Oxf); 2023 Oct; 99(4):378-385. PubMed ID: 37421211
[TBL] [Abstract][Full Text] [Related]
15. Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.
Tomasik A; Stelmachowska-Banaś M; Maksymowicz M; Czajka-Oraniec I; Raczkiewicz D; Zieliński G; Kunicki J; Zgliczyński W
Front Endocrinol (Lausanne); 2022; 13():957301. PubMed ID: 36187106
[TBL] [Abstract][Full Text] [Related]
16. Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression.
Muhammad A; Coopmans EC; Gatto F; Franck SE; Janssen JAMJL; van der Lely AJ; Hofland LJ; Neggers SJCMM
J Clin Endocrinol Metab; 2019 Mar; 104(3):915-924. PubMed ID: 30346538
[TBL] [Abstract][Full Text] [Related]
17. Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study.
Ilie MD; Tabarin A; Vasiljevic A; Bonneville JF; Moreau-Grangé L; Schillo F; Delemer B; Barlier A; Figarella-Branger D; Bisot-Locard S; Santos A; Chanson P; Raverot G
J Clin Endocrinol Metab; 2022 Nov; 107(11):2982-2991. PubMed ID: 36136828
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure.
Puig-Domingo M; Resmini E; Gomez-Anson B; Nicolau J; Mora M; Palomera E; Martí C; Halperin I; Webb SM
J Clin Endocrinol Metab; 2010 Nov; 95(11):4973-8. PubMed ID: 20739382
[TBL] [Abstract][Full Text] [Related]
19. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
Durmuş ET; Atmaca A; Kefeli M; Çalışkan S; Mete O; Aslan K; Fidan M; Çolak R; Durmuş B
Growth Horm IGF Res; 2022 Dec; 67():101502. PubMed ID: 36115256
[TBL] [Abstract][Full Text] [Related]
20. Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly.
Luo M; Yu J; Tang R
J Neurooncol; 2024 May; 167(3):415-425. PubMed ID: 38441839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
